Patents Assigned to Boryung Pharmaceutical Co. Ltd.
-
Patent number: 10420728Abstract: Disclosed is a method for preparing a tablet. The method can improve the compressibility of the active ingredients and produce tablets of uniform quality, bringing about the advantage of increasing tablet hardness with an increase in compression pressure, easily controlling disintegration time, and decreasing tablet friability by using the active ingredient fimasartan, a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof having a specific particle size distribution.Type: GrantFiled: January 11, 2016Date of Patent: September 24, 2019Assignee: Boryung Pharmaceutical Co., Ltd.Inventors: Jayhyuk Myung, Sung Chan Jeong, Yun Sam Kim
-
Publication number: 20180015043Abstract: Disclosed is a method for preparing a tablet. The method can improve the compressibility of the active ingredients and produce tablets of uniform quality, bringing about the advantage of increasing tablet hardness with an increase in compression pressure, easily controlling disintegration time, and decreasing tablet friability by using the active ingredient fimasartan, a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof having a specific particle size distribution.Type: ApplicationFiled: January 11, 2016Publication date: January 18, 2018Applicant: Boryung Pharmaceutical Co., LtdInventors: Jayhyuk Myung, Sung Chan Jeong, Yun Sam Kim
-
Patent number: 9592233Abstract: Provided is a pharmaceutical combination preparation including fimasartan and rosuvastatin as active ingredients together with meglumine. The combination preparation exhibits an outstanding effect in treating cardiovascular disease by improving the disintegration and the dissolution which obtained better drug bioavailability and drug safety.Type: GrantFiled: March 14, 2014Date of Patent: March 14, 2017Assignee: Boryung Pharmaceutical Co., Ltd.Inventors: Jayhyuk Myung, Kyung Wan Nam, Cheol Woo Lee, Ju Won Kim
-
Patent number: 9457094Abstract: The present invention provides: a pharmaceutical composition having a superior physical property since fimasartan and hydrochlorothiazide, which are main components of a combination preparation, have superior content uniformity; and a preparation method thereof.Type: GrantFiled: April 30, 2013Date of Patent: October 4, 2016Assignee: Boryung Pharmaceutical Co., Ltd.Inventors: Je Hak Kim, Kyung Wan Nam, Seo Hun Park, Ju Won Kim, Sang Yeop Kim
-
Publication number: 20160022679Abstract: The present invention relates to a pharmaceutical combination preparation comprising fimasartan and rosuvastatin as active ingredients together with meglumine. The combination preparation of the present invention exhibits an outstanding effect in treating cardiovascular disease by improving the disintegration and the dissolution which obtained better drug bioavailability and drug safety.Type: ApplicationFiled: March 14, 2014Publication date: January 28, 2016Applicant: Boryung Pharmaceutical Co., Ltd.Inventors: Jayhyuk MYUNG, Kyung Wan NAM, Cheol Woo LEE, Ju Won KIM
-
Patent number: 9227955Abstract: Disclosed are an anti-angiogenic compound, represented by Chemical Formula I, or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutically acceptable composition including the same. Because the compound of Chemical Formula I potently suppresses the angiogenesis, the compound of Chemical Formula I is applicable to the prevention and treatment of diseases caused by aberrant activity of vascular endothelial growth factor, and available as an anti-angiogenic agent.Type: GrantFiled: July 27, 2012Date of Patent: January 5, 2016Assignee: Boryung Pharmaceutical Co., Ltd.Inventors: Ji Han Kim, Je Hak Kim, Joon Kwang Lee, Hahn-Sun Jung, Nam Seok Han, Yong Park, Seung-Hoon Kang, Hee Jin Jeong, Kyung-Tae Lee, Hye Eun Choi, Yong Ha Chi, Joo Han Lee, Soo Heui Paik
-
Publication number: 20140256711Abstract: Disclosed are an anti-angiogenic compound, represented by Chemical Formula I, or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutically acceptable composition including the same. Because the compound of Chemical Formula I potently suppresses the angiogenesis, the compound of Chemical Formula I is applicable to the prevention and treatment of diseases caused by aberrant activity of vascular endothelial growth factor, and available as an anti-angiogenic agent.Type: ApplicationFiled: July 27, 2012Publication date: September 11, 2014Applicant: Boryung Pharmaceutical Co., Ltd.Inventors: Ji Han Kim, Je Hak Kim, Joon Kwang Lee, Hahn-Sun Jung, Nam Seok Han, Yong Park, Seung-Hoon Kang, Hee Jin Jeong, Kyung-Tae Lee, Hye Eun Choi, Yong Ha Chi, Joo Han Lee, Soo Heui Paik
-
Patent number: 8765776Abstract: Provided is an antihypertensive pharmaceutical composition containing Fimasartan, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as an angiotensin II receptor blocker, and Amlodipine, an isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as a calcium channel blocker.Type: GrantFiled: August 8, 2011Date of Patent: July 1, 2014Assignee: Boryung Pharmaceutical Co., Ltd.Inventors: Seung Ho Kim, Ji Han Kim, Je Hak Kim, Kyung Wan Nam, Yong Ha Chi, Joo Han Lee, Soo Heui Paik, So Jeong Yi, Tae Eun Kim, Seo Hyun Yoon, Joo Youn Cho, Sang Goo Shin, In Jin Jang, Kyung Sang Yu
-
Publication number: 20140044784Abstract: Disclosed is a combined formulation for oral administration to treat cardiovascular disease, including (a) cholesterol lowering agent mini-tablet having a diameter of 7.5 mm or less, which contain a cholesterol lowering agent, a stabilizer thereof and a pharmaceutically acceptable excipient and have a coating layer on the surface thereof, and (b) antithrombotic agent mini-tablets or mini-pellets having a diameter of 7.5 mm or less, which contain an antithrombotic agent and a pharmaceutically acceptable excipient and include an enteric coating film on the surface thereof. This formulation can improve treatment compliance depending on a combination prescription, and is controlled so that the cholesterol lowering agent is released in the gastrointestinal tracts and the antithrombotic agent is released in the intestines, thus suppressing the reactions and the side-effects between the drugs, inducing synergic effects of these drugs in vivo, and achieving improved stability.Type: ApplicationFiled: March 14, 2012Publication date: February 13, 2014Applicant: BORYUNG PHARMACEUTICAL CO., LTDInventors: Je Hak Kim, Kyung Wan Nam, Ju Won Park
-
Patent number: 8003850Abstract: Provided is a method for producing a target protein via cultivation of transgenic plant cells comprising a promoter capable of expressing the protein under sugar-free conditions in the response to the depletion of sugar and a gene encoding the target protein, without exchange of a cell growth medium with a sugar-depleted medium comprising the addition of an amino acid mixture to the sugar-rich medium used to grow the plant cells.Type: GrantFiled: September 19, 2007Date of Patent: August 23, 2011Assignee: Boryung Pharmaceutical Co., Ltd.Inventors: Sang-Lin Kim, Hyun-Kwang Tan, Sang-Min Lim, Wuk-Sang Ryu, Hahn-Sun Jung, Song-Jae Lee, Cheon-Ik Park, Seung-Hoon Kang, Dong-Il Kim
-
Publication number: 20100189717Abstract: The present invention provides a recombinant vector pBI-3D-hGalT or pBI-35S-hGalT containing a human ?1,4-galactosyltransferase gene; a cell line transformed with a recombinant vector pMYN414 containing a cytotoxic T-lymphocyte anti-gen A-immunoglobulin (CTLA4Ig) fusion protein gene and the recombinant vector pBI-3D-hGalT or pBI-355-hGalT; and a method for producing a plant-derived recombinant human CTLA4Ig (CTLA4Igp) fusion protein with a human glycan structure using the same. The plant cell-derived recombinant human CTLA4Ig fusion protein (CTLA4Igp), which has a human glycan structure and is produced according to the present invention, exhibits an improved in vivo half life as compared to conventional plant-derived proteins, due to the presence of a human-like glycan structure.Type: ApplicationFiled: July 9, 2008Publication date: July 29, 2010Applicant: Boryung Pharmaceutical Co., Ltd.Inventors: Sang-Lin Kim, Hyun-Kwang Tan, Sang-Min Lim, Wuk-Sang Ryu, Hahn-Sun Jung, Song-Jae Lee, Cheon-Ik Park, Seung-Hoon Kang, Dong Il Kim
-
Publication number: 20090181428Abstract: Provided is a method for producing a target protein via cultivation of transgenic plant cells comprising a promoter capable of expressing the protein under sugar-free conditions or in response to the depletion of sugar and a gene encoding the target protein, without exchange of a cell growth medium with a sugar-depleted medium. The method comprises 1) culturing transgenic plant cells in a sugar-rich medium to grow plant cells; and 2) culturing the transgenic plant cells with addition of an amino acid mixture to the culture of Step 1 without exchange of a cell growth medium with a sugar-depleted medium, thereby expressing a target protein.Type: ApplicationFiled: September 19, 2007Publication date: July 16, 2009Applicant: BORYUNG PHARMACEUTICAL CO., LTD.Inventors: Sang-Lin Kim, Hyun-Kwang Tan, Sang-Min Lim, Wuk-Sang Ryu, Hahn-Sun Jung, Song-Jae Lee, Cheon-Ik Park, Seung-Hoon Kang, Dong-Il Kim
-
Patent number: 7485656Abstract: An antibacterial composition for external application, particularly, a remedial formulation for external use containing fluconazole is disclosed. The formulation comprises a base material, 0.1-5.0 percent by weight of fluconazole and 1.0-40.0 percent by weight of any one compound selected from a group consisting of fatty acid, fatty alcohol, higher fatty acid ester and lower alcohol based on weight of the base material. The composition according to the present invention has various advantages of a favorable absorption into a system through the skin of a human body and delivery of active material into horny layer of the skin, a reduced skin stimulation and an excellent stability. Therefore, the composition is efficiently useable in a medical treatment application for dermatomycosis-related infectious diseases including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and/or candidiasis and the like.Type: GrantFiled: February 7, 2002Date of Patent: February 3, 2009Assignee: Boryung Pharmaceutical Co., Ltd.Inventors: Sang-Lin Kim, Hyun-Kwang Tan, Jun-Sik Kim, Ho-Beom Lee, Geun-Hong Min, Hae-Won Ryou
-
Patent number: 7309788Abstract: A process for preparing pyrimidinone compound and salts thereof The method of the present invention enables the convenience to produce the pyrimidinone derivatives in high yields, which pyrimidinone compounds are useful for treating cardiovascular diseases caused by binding angiotensin II to its receptors, through antagonistic activity against angiotensin II receptors.Type: GrantFiled: September 21, 2001Date of Patent: December 18, 2007Assignee: Boryung Pharmaceutical Co., Ltd.Inventors: Sang-Lin Kim, Ji-Han Kim, Jung-Bok Lee, Byoung-Wug Yoo, Hyun-Kwang Tan
-
Patent number: 6294542Abstract: The present invention relates to a novel pyrimidinone compounds and the pharmaceutical acceptable salts thereof having remarkable antagonistic action against angiotensin II receptor, thereby, being useful in treating cardiovascular disease caused by binding angiotensin II to its receptor.Type: GrantFiled: December 20, 1999Date of Patent: September 25, 2001Assignee: Boryung Pharmaceutical Co. Ltd.Inventors: Jae-hyoung Lee, Kyung-jin Jang, Byoung-wug Yoo, Ji-han Kim, Jae-seog Kang, Sang-lin Kim
-
Patent number: 5869476Abstract: The invention relates to pyrimidinone derivatives and the pharmaceutically acceptable salts thereof having remarkable antagonistic action against angiotensin II receptor, and thus useful in treating cardiovascular diseases caused by angiotensin II.Type: GrantFiled: April 25, 1997Date of Patent: February 9, 1999Assignee: Boryung Pharmaceutical Co., Ltd.Inventors: Woo Hyun Paik, Ji Han Kim, Jae Hyoung Lee, Kyung Jin Jang, Kwang Jae Cho, Jae Seog Kang, Byoung Wug Yoo, Je Bum Park, Kyung Jin Kim, Kun Ja Lee
-
Patent number: 5739120Abstract: The present invention relates to new liponucleotide analog compounds having useful antiviral activity, represented by general formula (I): ##STR1## wherein R.sup.1 is a saturated or unsaturated alkyl having 6-22 C atoms; R.sup.2 is a saturated or unsaturated alkyl having 12-20 C atoms; R.sup.3 and R.sup.4 are each hydrogen or hydroxy; and B is one of the nucleoside bases of formula (a): ##STR2## wherein R.sup.5 is a hydrogen, halogen, hydroxy, amino, mercapto, or C.sub.1 -C.sub.4 alkyl amino; R.sup.6 is a hydrogen, halogen or amino; W is a nitrogen or C--R.sup.8 where R.sup.8 is hydrogen, halogen, amino or C.sub.1 -C.sub.4 alkyl, and pharmaceutically acceptable salts thereof.Type: GrantFiled: April 30, 1997Date of Patent: April 14, 1998Assignee: Boryung Pharmaceutical Co., Ltd.Inventors: Woo Hyun Paik, Won Sup Shin, Jae Seung Lee, Hee Sang Chai
-
Patent number: 4556516Abstract: A process for the preparation of acylureido penicillin derivatives is disclosed. In particular this invention concerns an economical process for the preparation with high yield of penicillin derivatives of the formula ##STR1## where R.sup.1 represents phenyl or hydroxyphenyl and R.sup.2 a member selected from the group consisting of hydrogen, a protecting group, sodium, potassium and calcium. The compounds are useful as anti-bacterial agents for human and animals.Type: GrantFiled: February 7, 1984Date of Patent: December 3, 1985Assignee: Boryung Pharmaceutical Co., Ltd.Inventor: Don K. Kim